Literature DB >> 25241056

Fenofibrate--a lipid-lowering drug--reduces voluntary alcohol drinking in rats.

Eduardo Karahanian1, Maria Elena Quintanilla2, Katia Fernandez3, Yedy Israel2.   

Abstract

The administration of disulfiram raises blood acetaldehyde levels when ethanol is ingested, leading to an aversion to alcohol. This study was aimed at assessing the effect of fenofibrate on voluntary ethanol ingestion in rats. Fenofibrate reduces blood triglyceride levels by increasing fatty acid oxidation by liver peroxisomes, along with an increase in the activity of catalase, which can oxidize ethanol to acetaldehyde. UChB drinker rats were allowed to consume alcohol 10% v/v freely for 60 days, until consumption stabilized at around 7 g ethanol/kg/24 h. About 1-1.2 g ethanol/kg of this intake is consumed in the first 2 h of darkness of the circadian cycle. Fenofibrate subsequently administered (50 mg/kg/day by mouth [p.o.]) for 14 days led to a 60-70% (p < 0.001) reduction of 24-h ethanol consumption. When ethanol intake was determined within the first 2 h of darkness, the reduction was 85-90% (p < 0.001). We determined whether animals chronically allowed access to ethanol and subsequently treated with fenofibrate, would a) increase liver catalase activity, and b) increase blood acetaldehyde levels after a 24-h ethanol deprivation and the subsequent administration of 1 g ethanol/kg. The oral administration of 1 g ethanol/kg produced a rapid increase in blood (arterial) acetaldehyde in fenofibrate-treated animals versus controls also administered 1 g/kg ethanol (70 μM vs. 7 μM; p < 0.001). Liver catalase activity following fenofibrate treatment was increased 3-fold (p < 0.01). Other hepatic enzymes responsible for the metabolism of ethanol (alcohol dehydrogenase and aldehyde dehydrogenase) remained unchanged. No liver damage was induced, as measured by serum glutamic-pyruvic transaminase (GPT) activity. The effect of fenofibrate in reducing alcohol intake was fully reversible. Overall, in rats allowed chronic ethanol intake, by mouth (p.o.), fenofibrate administration increased liver catalase activity and reduced voluntary ethanol intake. The administration of 1 g ethanol/kg (p.o.) to these animals increased blood acetaldehyde levels in fenofibrate-treated animals, suggesting the possible basis for the reduction in ethanol intake.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alcoholism; Catalase; Fenofibrate; Fibrates; Peroxisome proliferator-activated receptor; Treatment

Mesh:

Substances:

Year:  2014        PMID: 25241056     DOI: 10.1016/j.alcohol.2014.08.004

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  13 in total

1.  The peroxisome proliferator-activated receptor alpha agonist fenofibrate attenuates alcohol self-administration in rats.

Authors:  Colin N Haile; Therese A Kosten
Journal:  Neuropharmacology       Date:  2017-01-11       Impact factor: 5.250

Review 2.  Rat animal models for screening medications to treat alcohol use disorders.

Authors:  Richard L Bell; Sheketha R Hauser; Tiebing Liang; Youssef Sari; Antoniette Maldonado-Devincci; Zachary A Rodd
Journal:  Neuropharmacology       Date:  2017-02-16       Impact factor: 5.250

Review 3.  From gene networks to drugs: systems pharmacology approaches for AUD.

Authors:  Laura B Ferguson; R Adron Harris; Roy Dayne Mayfield
Journal:  Psychopharmacology (Berl)       Date:  2018-03-01       Impact factor: 4.530

4.  Transcriptional Regulators as Targets for Alcohol Pharmacotherapies.

Authors:  Antonia M Savarese; Amy W Lasek
Journal:  Handb Exp Pharmacol       Date:  2018

5.  PPAR Agonists: II. Fenofibrate and Tesaglitazar Alter Behaviors Related to Voluntary Alcohol Consumption.

Authors:  Yuri A Blednov; Mendy Black; Jillian M Benavidez; Eleni E Stamatakis; R Adron Harris
Journal:  Alcohol Clin Exp Res       Date:  2016-02-09       Impact factor: 3.455

6.  PPAR Agonists: I. Role of Receptor Subunits in Alcohol Consumption in Male and Female Mice.

Authors:  Yuri A Blednov; Mendy Black; Jillian M Benavidez; Eleni E Stamatakis; R Adron Harris
Journal:  Alcohol Clin Exp Res       Date:  2016-02-09       Impact factor: 3.455

Review 7.  Medications for alcohol use disorders: An overview.

Authors:  Mohammed Akbar; Mark Egli; Young-Eun Cho; Byoung-Joon Song; Antonio Noronha
Journal:  Pharmacol Ther       Date:  2017-12-02       Impact factor: 12.310

Review 8.  Neuroimmune signaling in alcohol use disorder.

Authors:  Emma K Erickson; Emily K Grantham; Anna S Warden; R A Harris
Journal:  Pharmacol Biochem Behav       Date:  2018-12-24       Impact factor: 3.533

Review 9.  Immune treatments for alcohol use disorder: A translational framework.

Authors:  Lindsay R Meredith; Elizabeth M Burnette; Erica N Grodin; Michael R Irwin; Lara A Ray
Journal:  Brain Behav Immun       Date:  2021-07-31       Impact factor: 19.227

10.  Fenofibrate Administration Reduces Alcohol and Saccharin Intake in Rats: Possible Effects at Peripheral and Central Levels.

Authors:  Mario Rivera-Meza; Daniel Muñoz; Erik Jerez; María E Quintanilla; Catalina Salinas-Luypaert; Katia Fernandez; Eduardo Karahanian
Journal:  Front Behav Neurosci       Date:  2017-07-14       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.